🧫 Experiment Protocol
ValidationMAP6rodent in vivo modelproposed
This experiment used an in vivo assay system to examine the effects of MAP6 depletion on neuronal migration rates. The study was conducted to validate findings from cell culture experiments and to understand how MAP6's role in microtubule stabilization affects neuronal migration in a more physiologically relevant context. The researchers depleted MAP6 in vivo and measured neuronal migration rates, expecting to see effects opposite to those observed with tau depletion, consistent with their antagonistic relationship in regulating microtubule dynamics.
PRIMARY OUTCOME
rate of neuronal migration
EXPECTED OUTCOMES
## Primary Outcomes
**Migration Impairment**: MAP6 knockdown reduces neuronal migration distance by ≥35% vs. scramble controls at P7 (p < 0.01). Electroporated neurons accumulate in deeper cortical layers (≥40% in layers V-VI vs. ~20% in controls).
**Cytoskeletal Phenotype**: shMAP6 neurons show disrupted microtubule organization (reduced acetylated tubulin +40% in western blot) and altered leading process morphology (shorter leading processes, -30%, p < 0.05).
## Secondary Outcomes
**Rescue Specificity**: Co-electroporation of shMAP6-resistant MAP6 restores migration to ≥75% of scramble control levels, confirming phenotype is specifically due to MAP6 depletion.
**Temporal Requirement**: MAP6 depletion during migration window (E14.5-P7) is critical; knock-in at P7 (after migration complete) produces minimal phenotype, indicating developmentally regulated function.
SUCCESS CRITERIA
## Primary Success Criteria
**Knockdown Efficiency**: MAP6 shRNA must achieve ≥65% protein reduction in cortical neurons (western blot) with no off-target effects on related microtubule proteins (MAP2, Tau) at standard MOI.
**Migration Phenotype**: MAP6 knockdown must produce ≥25% reduction in migration distance (measured from ventricular zone to final position) with statistical significance (p < 0.05, Student's t-test, n≥3 embryos per condition).
## Secondary Success Criteria
**Layer-Specific Accumulation**: shMAP6 neurons must show significant enrichment in deeper cortical layers (V-VI) compared to scramble controls, with ≥15% difference in layer distribution.
**Rescue Confirmation**: MAP6 rescue construct must restore migration to ≥70% of control levels, demonstrating on-target specificity.
PROTOCOL
# In Vivo Neuronal Migration Assay with MAP6 Depletion Protocol
## Phase 1: MAP6 shRNA Viral Production and Pilot Knockdown (Days 1-21)
**shRNA Design**: Design 3 independent shRNAs targeting MAP6 (MISSION shRNA, Sigma-Aldrich): target sequences in 3' UTR and coding sequence. Include scrambled control shRNA with no homology to mouse genome. Clone into AAV2/9 vector under H1 promoter.
**Viral Production**: Co-transfect HEK293T cells (10 cm dishes, 80% confluent) with shRNA AAV plasmid, pAAV2/9 helper, and pXR5 rep/cap using PEI (1:3 ratio). Harvest at 72 hours, concentrate via iodixanol gradient (40/60% cushion). Titer via qPCR (genome copies/mL, target ≥10¹² GC/mL).
**Pilot Knockdown Verification**: Transduce primary cortical neurons (DIV 5) with AAV-shMAP6 or AAV-scramble at MOI 5. Assess knockdown at DIV 10, 14, 18 via qRT-PCR (MAP6 #Mm01238749_m1, normalized to GAPDH) and western blot (anti-MAP6, 1:500, Abcam #ab199937). Select shRNA with ≥70% knockdown and ≤20% off-target effects.
## Phase 2: In Utero Electroporation and Migration Analysis (Days 22-49)
**In Utero Electroporation**: Anesthetize E14.5 pregnant C57BL/6J mice (Crawford Long Hospital). Expose uterine horns, inject AAV-shMAP6 (or AAV-scramble, 1 μL, + 0.025% Fast Green dye) into lateral ventricle of each embryo. Apply electric pulses (5 pulses, 50 ms, 950 mV, 1 Hz) via CUY21EDIT electroporator with forceps electrodes.
**Tissue Collection**: At E18.5 and P0, P7, harvest brains from electroporated pups (identified by GFP co-expression from IRES-eGFP cassette). Fix in 4% PFA (24 hours, 4°C), cryoprotect in 30% sucrose, embed in OCT.
**Migration Analysis**: Cut coronal sections (20 μm) on cryostat. Immunostain for GFP (1:500, Abcam #ab13970) to identify electroporated neurons. Counterstain with DAPI. Image on Vectra 3.0 (10× objective). Quantify: (a) distribution of electroporated neurons across cortical layers (layer I through VIb), (b) distance traveled from ventricular zone, (c) morphology (leading process length, branch points).
## Phase 3: Functional Consequences and Rescue (Days 50-70)
**Cortical Lamination Assessment**: In P7 brain sections, assign electroporated neurons to cortical layers based on DAPI staining patterns and Ctip2/Satb2 immunohistochemistry (layer 5/6b markers). Compare distribution between shMAP6 and scramble groups.
**MAP6 Rescue Experiment**: Generate AAV-shMAP6-resistant MAP6 cDNA (silent mutations in shRNA target site). Co-electroporate shMAP6 + rescue construct. Assess whether MAP6 overexpression rescues migration phenotype (confirms specificity).
**Cell Survival Analysis**: At P7, quantify apoptotic neurons in electroporated population via cleaved caspase-3 immunostaining (1:200, Cell Signaling #9661). Calculate survival percentage relative to scramble controls.